Fewer Lucentis injections with new regimen
March 12th 2008Preliminary results of a study using the NSAID Xibrom (bromfenac ophthalmic solution 0.09%; ISTA Pharmaceuticals) therapy in combination with Lucentis (ranibizumab; Novartis) in patients with wet age-related macular degeneration (AMD), suggests that it may result in fewer injections being required.
Cataract incision size is just right thanks to new technology
March 10th 2008Incision sizes needed to remove cataracts have been significantly reduced by new technology, such as the vision enhancement system (Stellaris; Bausch & Lomb) which allows surgeons to make two 1.8 mm cuts on either side of the eye.
Resistance fuelling contact lens infections
March 4th 2008A study published in the January issue of Antimicrobial Agents & Chemotherapy, has found that the high proportion of corneal infections linked to contact lens solutions are fuelled and made resistant to treatment by the formation of a highly resistant structure of microbial cells held together with a glue-like matrix material, called biofilms.
IOP must be monitored in refractive surgery patients
March 3rd 2008In eyes that have undergone corneal refractive surgery, non-Goldmann measurements of intraocular pressure (IOP) and continued examination of the optic nerve is essential as changes of the corneal shape can lead to falsely low IOP values.
Debate continues on role of incision type in endophthalmitis risk
March 1st 2008Cataract surgeons agree that proper incision construction is paramount for achieving good postoperative stability that will reduce the risk for endophthalmitis. The safety of the clear cornea incision technique versus use of other incision types remains controversial, however.